

Counterpoint Global Insights

Psychedelics

EDGE | JULY 2022

WELCOME TO THE EDGE.

Morgan Stanley Investment Management's Counterpoint Global shares their proprietary views on a big idea that has the potential to trigger far-reaching consequences—ideas such as blockchain, autonomous vehicles, machine learning and gene editing.

Counterpoint Global's long-term ownership mindset emphasizes perspective, insight and thinking across categories, while our investment process focuses on identifying unique companies with sustainable competitive advantages. Through the EDGE, we share our framework for thinking about change and our process for recognizing patterns that may drastically alter the investment landscape over the longer term.

This work complements our team's more traditional, fundamental research to create a framework for long-term investing that is grounded in intellectual curiosity and flexibility, perspective, self-awareness and partnership.

Research into the potential therapeutic benefits of psychedelics is experiencing a renaissance. Psychedelics showed promise in treating mental illness as early as the 1950s, but research was essentially shut down in the 1960s. In 1970, the Controlled Substances Act classified psychedelics as Schedule 1 drugs, which have "no currently accepted medical use and a high potential for abuse." Now, a second wave of psychedelic research is underway, including a number of promising academic studies related to treating anxiety and depression. As a result, the use of psychedelics for medical purposes has renewed credibility and there is currently significant clinical trial activity for a number of psychedelic compounds that have a credible chance of achieving approval from the Food and Drug Administration (FDA). The potential market for psychedelic drugs is much larger than just patients with depression. Attention deficit hyperactivity disorder (ADHD), addiction, anxiety, and various chronic pain afflictions are likely to follow depression and post-traumatic stress disorder (PTSD) as indications approved by the FDA.



What is it?

Psychedelics are psychoactive substances that alter perception and mood. They affect numerous cognitive processes by promoting new pathways between neurons. Neurons are the fundamental cells in the brain and are connected to one another via synapses. These novel connections create specific psychological, visual, and auditory changes that alter the state of consciousness. The term “psychedelic” comprises hundreds of drugs, of which a few occur in nature and the majority are created in labs as synthesized derivatives of the classical psychedelics.

The classical psychedelics, including psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), have had the largest scientific and cultural influence. Contrary to what is implied by their designation as Schedule 1 drugs, they are generally considered physiologically safe and do not lead to addiction.¹ Widespread use of these drugs in the 1960s caused a severe backlash and heightened scrutiny, effectively halting all research. Current studies and trials strategically target sympathetic patient populations suffering from depression, trauma, or addiction and focus on the medicinal value of

Psychedelics offer a fundamental change in how mental health disorders are treated.

psychedelics rather than legalization and widespread access. At the same time that psychedelic drugs are in clinical trials seeking FDA approval for medical use, initiatives such as the Oregon Model seek to expand public access beyond medical treatment to include religious, spiritual, and recreational use.

History

Knowledge of psychedelic plants predates written text, and they have been used in religious and therapeutic contexts for thousands of years all over the world. Psychedelics are known for their ability to alter consciousness and their capacity to open the mind. They entered mainstream awareness in the U.S. in the 1960s and were largely associated with the counterculture movement. During this period, researchers published more than a thousand clinical papers and

several dozen books on the benefits of psychedelic drugs in a therapeutic context, attracting the interest and support of many psychiatrists. Despite mounting evidence that clinical use of psychedelics could help many patients, public perception grew more negative as the recreational use of psychedelics became widespread. This dim view of psychedelics led the federal government to designate them as Schedule 1 drugs. This decision effectively stopped all research for the next 30 years. However, in the last 15 years several academic institutions have conducted small studies exploring the potential of psychedelics to address a number of medical indications, including treatment-resistant depression and PTSD. The impressive results of these small studies have generated great interest in further exploring the potential of psychedelic therapy.

¹ Source: Nichols, David E. “Psychedelics.” *Pharmacological reviews* vol. 68,2 (2016)

Compounds

Numerous psychedelic compounds are in early studies and clinical trials today. Psychedelics such as psilocybin, DMT, and mescaline are found in nature while others, including LSD, are synthesized in a lab. Most of these psychedelics have different chemical structures but cause remarkably similar effects.

Initial commercial focus is on three compounds, two of which have been studied more extensively than the other. The first is the classical psychedelic psilocybin, which has attracted the greatest academic interest for the treatment of depression. Second is the psychedelic empathogen hybrid methylenedioxymethamphetamine (MDMA), which has shown great potential to treat PTSD. MDMA is the furthest along of the compounds, currently in Phase 3 clinical trials and expected to be approved by the FDA in 2023.

The third noteworthy psychedelic is 5-MEO-DMT. Originally discovered in the venom of a Sonoran Desert toad, the drug is now predominantly synthesized in the lab for medical use. While lacking in extensive anecdotal studies and research, this psychedelic is of particular interest due to its very short duration time of roughly 15 to 30 minutes compared to the six hour-plus experience of a classical psychedelic. While the inhalation of DMT has an onset measured in seconds and effects measured in minutes, the experience is significantly more intense than its longer-acting peers. DMT can cause users to enter a hallucinatory realm fully detached from reality, characterized by hyperbolic geometry and described as defying visual or verbal description. In addition, the company furthest along in developing 5-MEO-DMT to treat depression does not plan to include therapy as part of treatment. This substantially reduces the time and cost burden to the patient and clinician.

Mechanisms of action

Magnetic resonance imaging (MRI) scans show that a brain on psychedelics

functions completely differently than one during ordinary consciousness. While the mechanism of action is not fully understood, we know that the primary effect of psychedelics comes from the brain's serotonin 5-HT_{2A} receptors. The hypothesis is that activating these receptors allows the brain to “reset,” leading to remission of the symptoms of depression that can last for months after a single psychedelic treatment.

Psychedelics bind to these serotonin receptors and shut down the Default Mode Network (DMN), which governs our sense of identity. This disrupts the traditional patterns of thinking and enables the activation of new neural pathways. The result is a shift of consciousness and perception. The psychedelic state has been compared to the mind of a baby, with billions of synaptic connections yet to be pruned as patterns of thought are established. This altered state of perception and fluid sense of identity have profound implications for mental illness rooted in rigid thought patterns such as depression and anxiety. The result is a patient who is able to shift to a different state of awareness that is often effective in reducing depressive symptoms drastically.

Why it's disruptive

The ability to perceive reality in a new way can change the life of a clinically depressed patient. The realizations a patient has with psychedelic medicine are subsequently integrated through therapy, potentially ending the self-perpetuating cycles of depressed thought. While multiple pharmacological and nonpharmacological options exist to treat mental illness, there have been no truly new psychiatric drug treatments since the 1980s, when Prozac and other selective serotonin reuptake inhibitors (SSRIs), the most common type of antidepressants, came to market. Unfortunately, many patients do not respond to these medications or don't like how they feel when on them.

Unlike SSRIs, which dull or mask the symptoms of depression and must be taken chronically, psychedelic-assisted therapy can change a patient's fundamental outlook over the course of one to a handful of sessions. The specifics of dosing, setting, and the particular psychedelic compound are still to be determined and are likely to vary by individual.

Unmet need

The number of mood disorders and suicide-related events has increased significantly in the last decade, exacerbated by the stress of modern life and the isolation brought on by COVID. Major Depressive Disorder and other mental health disorders can be debilitating and life threatening. Suicide is now the second-leading cause of death for people aged 10 to 34 years.² The number of people diagnosed with depression has increased drastically over the past decade. According to The Substance Abuse and Mental Health Services Administration, an estimated 52.9 million adults, or in one in five, suffer from a mental health illness in the U.S. Mental Health America reports that 46 percent of Americans meet the criteria for a diagnosable mental health condition at some point in their life, and half of those people will develop conditions by the age of 14. Depression is now one of the leading causes of disability, and the global cost to treat mental health illness is anticipated to reach \$6 trillion by 2030.³

Unfortunately most people, including those with access to care, are not getting better. Many patients simply do not respond to current treatment options. Psychedelic therapies are an alternative approach to treating mental health that target unmet needs and redress the lack of innovation in the field. Various psychedelic compounds may also have the ability to treat addiction, chronic pain conditions like fibromyalgia, and even ADHD. Studies to determine their efficacy in these areas are underway now.

² Source: National Center for Health Statistics, CDC, December 2020.

³ Source: World Health Organization, September 2021.

Problem they solve

Psychedelics offer a fundamental change in how mental health disorders are treated. Instead of aiming to mask or mute symptoms with chronic drug intake, they reset the mind with one or several treatments. Recent studies suggest that these positive effects have considerable durability, showing efficacy up to a year later. They also have an immediate effect in contrast to the onset time of four to 12 weeks for current treatments such as SSRIs for depression and anxiety. SSRIs treat depression by increasing levels of serotonin in the brain. Serotonin is one of the chemical messengers that carry signals between neurons. Despite being the best option available, SSRIs are not very effective and help only about 25 percent of patients who take them. Psychedelic medicine or assisted therapy could be the next course of treatment in cases where SSRIs fail. Early research by doctors affiliated with Johns Hopkins, New York University, and UCLA has shown psychedelic-assisted therapy to be effective and relatively durable with only one to a few treatments. These studies have been so promising that the FDA has designated both MDMA and psilocybin as breakthrough therapies. This designation allows researchers to expedite the development and review of drugs that are intended to treat a serious condition. To qualify, preliminary clinical evidence must indicate that the drug is safe and has the potential to demonstrate substantial improvement over available therapies.

Conclusion

Psychedelics have a long history of use in religious and ceremonial contexts around the world in addition to the treatment of numerous physical and mental conditions. Interest in and openness to psychedelics as medicine are increasing daily as the media's narrative has changed and promising research on their benefits continues to grow. Psychedelic-assisted therapy has the potential to literally rewire our brains through the creation of new neural pathways, allowing depressed patients to escape perpetual cycles of negative thought. Early results indicate that psychedelic therapy has the potential to fundamentally reshape how we think about and treat not only mental illness but a host of other conditions as well. In order for psychedelics to become mainstream, they will need to be validated in large-scale randomized controlled trials. Over the next few years, we might see the first psychedelic therapies pass FDA approval, giving clinicians additional tools to treat mental illness, and potentially the data to determine which psychedelic drugs would better treat certain indications and patients.

Potential markets


Research indicates the potential for a wide array of mental health disorders. Psychedelic drugs are currently being investigated for the treatment of everything from depression to cluster headaches to Alzheimer's disease. Scientists are also studying psychedelics for their beneficial effects for pain-related diseases, with the belief they can beneficially alter psychological mechanisms and neural pathways associated with persistent pain. Because psychedelics reorganize neural networks in the brain, they have the potential to target pain through changes in the brain's structure and function. Beyond mental illness and pain-related diseases, psychedelics have the potential to treat any disease where new neural pathways might improve function.

Challenges

While promising, psychedelics face numerous roadblocks to adoption. The most immediate challenge is navigating clinical trials and achieving FDA approval before advancing to administration and treatment protocols. To succeed, infrastructure and clinician support must be available and scalable. For example, therapists need specific training in order to administer psychedelic medicine, which is time consuming and not widely available. The treatment facility is also very important because it establishes the setting in which a patient will have their experience. Setting can shape the experience positively or negatively. These factors

will add to the costs and complexity of providing psychedelic-assisted therapy.

The first wave of psychedelic-assisted therapies last roughly six to eight hours and require clinic space and medical supervision during this period. In addition, there are follow-up therapy sessions. At the same time, the medical psychedelic community faces challenges from both the rising movement to decriminalize psychedelics and the challenge of overcoming a negative perception of psychedelics. Many clinicians and patients are wary of psychedelics as the result of years of negative press and Schedule 1 Drug status. The public will need to see psychedelic medicine as real medicine. Clinicians will have to rethink and expand their definition of what an antidepressant is and even how we should be treating depression. The competitive landscape also introduces headwinds for the commercial success of many of these companies. Even though most novel psychedelic compounds are patented, the drugs have similar chemical structures and, consequently, similar therapeutic effects, making it unclear how psychedelic companies will significantly differentiate their treatments and establish market share. Finally, the matter of reimbursement will be vital to achieve meaningful access and adoption. Once efficacy and duration are established, we will have a better idea of how psychedelic drugs and therapies will be priced and at what stage of treatment insurance companies will agree to reimburse patients.



OTHER DISRUPTORS

Other themes the team is currently researching include

- Drones
- Quantum Computing
- CAR-T Therapy
- Automation/robotics
- Blockchain
- Autonomous vehicles

Counterpoint Global

New York

INVESTORS	RESEARCH RESPONSIBILITIES	YEARS OF EXPERIENCE	YEARS WITH FIRM	YEARS WITH TEAM
DENNIS LYNCH	Lead Investor, Head of Counterpoint Global	28	24	24
SAM CHAINANI	Head of Counterpoint Global ~ New York, Technology	26	26	22
JASON YEUNG	Health Care	25	20	18
ARMISTEAD NASH	Business Services, Software	22	20	18
DAVID COHEN	Consumer	34	29	23
ALEX NORTON	Consumer, Industrials, Technology (ex Software)	27	22	22
MANAS GAUTAM	Head of Global Endurance, Generalist	10	7	7
ANNE EDELSTEIN	Health Care	11	4	4
ABHIK KUMAR	Software, Media	13	3	3
JENNY LEEDS	Healthcare	6	3	3
JOSHUA JARRETT	Director of Research, Generalist	17	2	2
RUOBING CHANG	Internet	10	6	2
ALEKS SAMETS	Payments	2	2	2
BETH FIFER	Health Care	10	1	1
MUHAMMADRAZA PANJU	Internet	3	1	1
PETE STOVELL	Generalist	28	1	1
LIZ HALL	Blockchain, Cryptocurrency, Gaming	15	<1	<1
MICHAEL MORITZ	Generalist	4	<1	<1
CONSILIENT RESEARCH				
MICHAEL MAUBOUSSIN	Head of Consilient Research	35	2	2
DAN CALLAHAN	Consilient Research	17	2	2
DISRUPTIVE CHANGE RESEARCH				
STAN DELANEY	Big Ideas, Emerging Themes	21	21	18
SASHA COHEN	Big Ideas, Emerging Themes	5	5	5
JUSTIN AMEZQUITA	Big Ideas, Emerging Themes	2	2	2
VASILEIOS PRASSAS	Big Ideas, Emerging Themes	8	1	1
SUSTAINABILITY RESEARCH				
THOMAS KAMEI	Head of Sustainability Research, Internet	10	10	10
DERRICK MAYO	Sustainability Research	17	8	1
CLIENT RELATIONSHIP AND BUSINESS MANAGEMENT				
MARK TODTFELD	Chief Operating Officer	27	17	3
KERRY ANN JAMES	Head of Client Relations, Portfolio Specialist	25	5	1
PRAJAKTA NADKARNI	Portfolio Specialist	18	15	11
MICK MORAN	Portfolio Specialist	8	8	<1
MCKENZIE BURKHARDT	Portfolio Specialist	19	19	19
XAVIER SALAZAR	Portfolio Analyst	4	4	<1
KATHRYNE DOWNS	Portfolio Specialist ~ Global Endurance	10	10	<1
EARL PRYCE	Portfolio Administrator	22	22	15
CHAYSE MORGAN	Portfolio Administrator	2	2	2
ERICA CASARENO	Portfolio Administrator	<1	<1	<1
AMBER YOUNG	Business Management	12	4	1

Asia

Global, International, Asia

KRISTIAN HEUGH Lead Investor, Head of Global Opportunity

- 11 Investors, 5 Portfolio Specialists, 1 Portfolio Operations Analyst

"Investor" refers to an analyst or portfolio manager of Counterpoint Global. Counterpoint Global members may change without notice from time to time. Years of Experience listed above refers to Industry Experience. Years of Experience, Years with Firm and Years with Team are as of June 2022.

Risk Considerations

There is no assurance that a Portfolio will achieve its investment objective. Portfolios are subject to **market risk**, which is the possibility that the market values of securities owned by the Portfolio will decline and that the value of Portfolio shares may therefore be less than what you paid for them. Market values can change daily due to economic and other events (e.g. natural disasters, health crises, terrorism, conflicts and social unrest) that affect markets, countries, companies or governments. It is difficult to predict the timing, duration, and potential adverse effects (e.g. portfolio liquidity) of events. Accordingly, you can lose money investing in this Portfolio. Please be aware that this Portfolio may be subject to certain additional risks.

In general, **equities securities'** values also fluctuate in response to activities specific to a company. Investments in **foreign markets** entail special risks such as currency, political, economic, market and liquidity risks. The risks of investing in **emerging market countries** are greater than risks associated with investments in foreign developed countries. **Privately placed and restricted securities** may be subject to resale restrictions as well as a lack of publicly available information, which will increase their illiquidity and could adversely affect the ability to value and sell them (liquidity risk). **Derivative instruments** may disproportionately increase losses and have a significant impact on performance. They also may be subject to counterparty, liquidity, valuation, correlation and market risks. **Illiquid securities** may be more difficult to sell and value than public traded securities (liquidity risk).

IMPORTANT INFORMATION

There is no guarantee that any investment strategy will work under all market conditions, and each investor should evaluate their ability to invest for the long-term, especially during periods of downturn in the market.

A separately managed account may not be appropriate for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing. A minimum asset level is required.

For important information about the investment managers, please refer to Form ADV Part 2.

The views and opinions and/or analysis expressed are those of the author as of the original publication date and are subject to change at any time due to market or economic conditions and may not necessarily come to pass. Furthermore, the views will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date of publication. The views expressed do not reflect the opinions of all investment personnel at Morgan Stanley Investment Management (MSIM) and its subsidiaries and affiliates (collectively "the Firm"), and may not be reflected in all the strategies and products that the Firm offers.

Forecasts and/or estimates provided herein are subject to change and may not actually come to pass.

This material is a general communication, which is not impartial and all information provided has been prepared solely for informational and educational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

This material has been prepared on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. However, no assurances are provided regarding the reliability of such information and the Firm has not sought to independently verify information taken from public and third-party sources.

This material is not a product of Morgan Stanley's Research Department and should not be regarded as a research material or a recommendation.

The Firm has not authorised financial intermediaries to use and to distribute this material, unless such use and distribution is made in accordance with applicable law and regulation. Additionally, financial intermediaries are required to satisfy themselves that the information in this material is appropriate for any person to whom they provide this material in view of that person's circumstances and purpose. The Firm shall not be liable for, and accepts no liability for, the use or misuse of this material by any such financial intermediary.

This material may be translated into other languages. Where such a translation is made this English version remains definitive. If there are any discrepancies between the English version and any version of this

material in another language, the English version shall prevail.

The whole or any part of this material may not be directly or indirectly reproduced, copied, modified, used to create a derivative work, performed, displayed, published, posted, licensed, framed, distributed or transmitted or any of its contents disclosed to third parties without the Firm's express written consent. This material may not be linked to unless such hyperlink is for personal and non-commercial use. All information contained herein is proprietary and is protected under copyright and other applicable law.

Morgan Stanley Investment Management is the asset management division of Morgan Stanley.

DISTRIBUTION

This material is only intended for and will only be distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.

MSIM, the asset management division of Morgan Stanley (NYSE: MS), and its affiliates have arrangements in place to market each other's products and services. Each MSIM affiliate is regulated as appropriate in the jurisdiction it operates. MSIM's affiliates are: Eaton Vance Management (International) Limited, Eaton Vance Advisers International Ltd, Calvert Research and Management, Eaton Vance Management, Parametric Portfolio Associates LLC, and Atlanta Capital Management LLC.

This material has been issued by any one or more of the following entities:

EMEA

This material is for Professional Clients/Accredited Investors only.

In the EU, MSIM and Eaton Vance materials are issued by MSIM Fund Management (Ireland) Limited ("FMIL"). FMIL is regulated by the Central Bank of Ireland and is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, DO2 VC42, Ireland.

Outside the EU, MSIM materials are issued by Morgan Stanley Investment Management Limited (MSIM Ltd) is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA.

In Switzerland, MSIM materials are issued by Morgan Stanley & Co. International plc, London (Zurich Branch) Authorised and regulated by the Eidgenössische Finanzmarktaufsicht ("FINMA"). Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland.

Outside the US and EU, Eaton Vance materials are issued by Eaton Vance Management (International) Limited ("EVM") 125 Old Broad Street, London, EC2N 1AR, UK, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority.

Italy: MSIM FMIL (Milan Branch), (Sede Secondaria di Milano) Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy. **The Netherlands:** MSIM FMIL (Amsterdam Branch), Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. **France:** MSIM FMIL (Paris Branch), 61 rue de Monceau 75008 Paris, France. **Spain:** MSIM FMIL (Madrid Branch), Calle Serrano 55, 28006, Madrid, Spain. **Germany:** MSIM FMIL (Ireland) Limited Frankfurt Branch, Große Gallusstraße 18, 60312 Frankfurt am

Main, Germany (Gattung: Zweigniederlassung (FDI) gem. § 53b KWG).
Denmark: MSIM FML (Copenhagen Branch), Gorrisen Federspiel, Axel Towers, Axeltorv2, 1609 Copenhagen V, Denmark.

MIDDLE EAST

Dubai: MSIM Ltd (Representative Office, Unit Precinct 3-7th Floor-Unit 701 and 702, Level 7, Gate Precinct Building 3, Dubai International Financial Centre, Dubai, 506501, United Arab Emirates. Telephone: +97 (0)14 709 7158).

U.S.

NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT

Latin America (Brazil, Chile Colombia, Mexico, Peru, and Uruguay)

This material is for use with an institutional investor or a qualified investor only. All information contained herein is confidential and is for the exclusive use and review of the intended addressee, and may not be passed on to any third party. This material is provided for informational purposes only and does not constitute a public offering, solicitation or recommendation to buy or sell for any product, service, security and/or strategy. A decision to invest should only be made after reading the strategy documentation and conducting in-depth and independent due diligence.

ASIA PACIFIC

Hong Kong: This material is disseminated by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to "professional investors" as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this material have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this material shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. **Singapore:** This material is disseminated by Morgan Stanley Investment Management Company and should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore ("SFA"); (ii) to a "relevant person" (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This publication has not been reviewed by the Monetary Authority of Singapore. **Australia:** This material is disseminated in Australia by

Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accept responsibility for its contents. This publication, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. Calvert Research and Management, ARBN 635 157 434 is regulated by the U.S. Securities and Exchange Commission under U.S. laws which differ from Australian laws. Calvert Research and Management is exempt from the requirement to hold an Australian financial services licence in accordance with class order 03/1100 in respect of the provision of financial services to wholesale clients in Australia.

Japan

For professional investors, this material is circulated or distributed for informational purposes only. For those who are not professional investors, this material is provided in relation to Morgan Stanley Investment Management (Japan) Co., Ltd. ("MSIMJ")'s business with respect to discretionary investment management agreements ("IMA") and investment advisory agreements ("IAA"). This is not for the purpose of a recommendation or solicitation of transactions or offers any particular financial instruments. Under an IMA, with respect to management of assets of a client, the client prescribes basic management policies in advance and commissions MSIMJ to make all investment decisions based on an analysis of the value, etc. of the securities, and MSIMJ accepts such commission. The client shall delegate to MSIMJ the authorities necessary for making investment. MSIMJ exercises the delegated authorities based on investment decisions of MSIMJ, and the client shall not make individual instructions. All investment profits and losses belong to the clients; principal is not guaranteed. Please consider the investment objectives and nature of risks before investing. As an investment advisory fee for an IAA or an IMA, the amount of assets subject to the contract multiplied by a certain rate (the upper limit is 2.20% per annum (including tax)) shall be incurred in proportion to the contract period. For some strategies, a contingency fee may be incurred in addition to the fee mentioned above. Indirect charges also may be incurred, such as brokerage commissions for incorporated securities. Since these charges and expenses are different depending on a contract and other factors, MSIMJ cannot present the rates, upper limits, etc. in advance. All clients should read the Documents Provided Prior to the Conclusion of a Contract carefully before executing an agreement. This material is disseminated in Japan by MSIMJ, Registered No. 410 (Director of Kanto Local Finance Bureau (Financial Instruments Firms)), Membership: the Japan Securities Dealers Association, The Investment Trusts Association, Japan, the Japan Investment Advisers Association and the Type II Financial Instruments Firms Association.

Explore our site at www.morganstanley.com/im